Artivion, Inc. (NYSE:AORT) Receives $40.63 Consensus Target Price from Analysts

Key Points

• Artivion, Inc. (NYSE:AORT) has received an average rating of "Buy" from seven research firms, with an average target price of $40.63.
• The company reported a significant earnings beat with $0.24 EPS for the last quarter, exceeding expectations of $0.11, alongside a revenue of $112.97 million.
• Recent insider activities include sales by the SVP and CEO, with the total insider sales in the last quarter amounting to $4.44 million, indicating potential shifts in management confidence or strategy.

Artivion, Inc. (NYSE:AORT - Get Free Report) has earned a consensus recommendation of "Buy" from the seven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $40.6333.

AORT has been the subject of several recent research reports. Canaccord Genuity Group raised their target price on shares of Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a research note on Monday, August 25th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and boosted their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Needham & Company LLC boosted their target price on shares of Artivion from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Finally, Oppenheimer reissued an "outperform" rating on shares of Artivion in a research note on Friday, August 8th.

Artivion Stock Performance

Shares of NYSE:AORT traded down $1.63 on Tuesday, hitting $40.68. 432,541 shares of the company were exchanged, compared to its average volume of 413,081. Artivion has a 1-year low of $21.97 and a 1-year high of $45.07. The stock's 50 day moving average price is $37.46 and its 200 day moving average price is $30.33. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $1.92 billion, a P/E ratio of -96.86 and a beta of 1.69.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. The firm's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, insider John E. Davis sold 10,802 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the transaction, the insider directly owned 208,778 shares in the company, valued at $9,117,335.26. The trade was a 4.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 23,356 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the transaction, the senior vice president owned 172,129 shares in the company, valued at $7,403,268.29. The trade was a 11.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,858 shares of company stock valued at $3,692,629. Insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Artivion by 4.1% in the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock valued at $42,460,000 after acquiring an additional 67,327 shares during the period. Next Century Growth Investors LLC raised its stake in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock valued at $25,140,000 after acquiring an additional 530,122 shares during the period. Bank of America Corp DE raised its stake in shares of Artivion by 22.8% in the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company's stock valued at $20,062,000 after acquiring an additional 119,634 shares during the period. Invesco Ltd. raised its stake in shares of Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company's stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Artivion by 10.0% in the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company's stock valued at $13,244,000 after acquiring an additional 42,170 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.